Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (381-390 of 868) with videos related to

Pageof 87
Sort By:
Blood|October 7, 2006
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)Klaus Podar, Marc S Raab, Jing Zhang, et al.
European Journal of Haematology|October 14, 2011
The Medical Research Council Myeloma IX trial: the impact on treatment paradigmsPaul G Richardson, Jacob P Laubach, Robert L Schlossman, et al.
British Journal of Haematology|May 4, 2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 studyPaul G Richardson, Asher A Chanan-Khan, Sagar Lonial, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 28, 2024
Retraction: Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA DamageYu-Tzu Tai, Gerrard Teoh, Boris Lin, et al.
Leukemia Research|April 16, 2013
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myelomaPaul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.
Blood|May 31, 2002
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myelomaRoberto Bellucci, Edwin P Alyea, Edie Weller, et al.
Blood|March 14, 2014
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemiaMariateresa Fulciniti, Nicola Amodio, Rajya Lakshmi Bandi, et al.
British Journal of Haematology|April 27, 2012
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agentsMerav Leiba, Jana Jakubikova, Steffen Klippel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 24, 2007
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trialsJohn Koreth, Corey S Cutler, Benjamin Djulbegovic, et al.
British Journal of Haematology|November 25, 2003
Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survivalRenate Burger, Frank Bakker, Andreas Guenther, et al.
Pageof 87

Showing results (381-390 of 868) with videos related to

Sort By:
Pageof 87
Blood|October 7, 2006
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)Klaus Podar, Marc S Raab, Jing Zhang, et al.
European Journal of Haematology|October 14, 2011
The Medical Research Council Myeloma IX trial: the impact on treatment paradigmsPaul G Richardson, Jacob P Laubach, Robert L Schlossman, et al.
British Journal of Haematology|May 4, 2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 studyPaul G Richardson, Asher A Chanan-Khan, Sagar Lonial, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 28, 2024
Retraction: Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA DamageYu-Tzu Tai, Gerrard Teoh, Boris Lin, et al.
Leukemia Research|April 16, 2013
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myelomaPaul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.
Blood|May 31, 2002
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myelomaRoberto Bellucci, Edwin P Alyea, Edie Weller, et al.
Blood|March 14, 2014
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemiaMariateresa Fulciniti, Nicola Amodio, Rajya Lakshmi Bandi, et al.
British Journal of Haematology|April 27, 2012
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agentsMerav Leiba, Jana Jakubikova, Steffen Klippel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 24, 2007
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trialsJohn Koreth, Corey S Cutler, Benjamin Djulbegovic, et al.
British Journal of Haematology|November 25, 2003
Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survivalRenate Burger, Frank Bakker, Andreas Guenther, et al.
Pageof 87